JP2021519786A - チエノピリミジノン化合物 - Google Patents

チエノピリミジノン化合物 Download PDF

Info

Publication number
JP2021519786A
JP2021519786A JP2020552869A JP2020552869A JP2021519786A JP 2021519786 A JP2021519786 A JP 2021519786A JP 2020552869 A JP2020552869 A JP 2020552869A JP 2020552869 A JP2020552869 A JP 2020552869A JP 2021519786 A JP2021519786 A JP 2021519786A
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
alkyl
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020552869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519786A5 (enExample
Inventor
チャン， カイル ダブリュー．エイチ．
チャン， カイル ダブリュー．エイチ．
アパラジタ ホスコテ チョウラシア，
アパラジタ ホスコテ チョウラシア，
ポール イー． エルドマン，
ポール イー． エルドマン，
リア ファン，
リア ファン，
イメルダ ラム，
イメルダ ラム，
フランク メルキューリオ，
フランク メルキューリオ，
ロバート サリバン，
ロバート サリバン，
エドゥアルド トーレス，
エドゥアルド トーレス，
Original Assignee
バイオセリックス， インコーポレイテッド
バイオセリックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオセリックス， インコーポレイテッド, バイオセリックス， インコーポレイテッド filed Critical バイオセリックス， インコーポレイテッド
Publication of JP2021519786A publication Critical patent/JP2021519786A/ja
Publication of JP2021519786A5 publication Critical patent/JP2021519786A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2020552869A 2018-03-30 2019-03-28 チエノピリミジノン化合物 Pending JP2021519786A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650922P 2018-03-30 2018-03-30
US62/650,922 2018-03-30
PCT/US2019/024612 WO2019191451A1 (en) 2018-03-30 2019-03-28 Thienopyrimidinone compounds

Publications (2)

Publication Number Publication Date
JP2021519786A true JP2021519786A (ja) 2021-08-12
JP2021519786A5 JP2021519786A5 (enExample) 2022-04-04

Family

ID=66102328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020552869A Pending JP2021519786A (ja) 2018-03-30 2019-03-28 チエノピリミジノン化合物

Country Status (8)

Country Link
US (1) US10584133B2 (enExample)
EP (1) EP3774815A1 (enExample)
JP (1) JP2021519786A (enExample)
CN (1) CN112313236A (enExample)
AU (1) AU2019243186A1 (enExample)
CA (1) CA3094988A1 (enExample)
TW (1) TW202003524A (enExample)
WO (1) WO2019191451A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021105335A1 (en) * 2019-11-27 2021-06-03 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
KR20230005210A (ko) * 2020-04-08 2023-01-09 레믹스 테라퓨틱스 인크. 스플라이싱을 조절하기 위한 화합물 및 방법
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
CN117203196A (zh) 2020-12-14 2023-12-08 拜欧斯瑞克斯公司 Pde4降解剂、药物组合物和治疗应用
AU2022207648A1 (en) 2021-01-13 2023-07-27 Monte Rosa Therapeutics Ag Isoindolinone compounds
WO2022255890A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
JP2024527628A (ja) * 2021-07-19 2024-07-25 メッドシャイン ディスカバリー インコーポレイテッド ヘテロアリール－３－ピペリジンジオン化合物その使用
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516821A (ja) * 2013-04-17 2016-06-09 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
WO2017161119A1 (en) * 2016-03-16 2017-09-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334596A (en) 1993-05-11 1994-08-02 Merck & Co., Inc. Fibrinogen receptor antagonists
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
MXPA04008797A (es) 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Inhibidores de histona desacetilasa.
WO2005030705A1 (en) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
US20050176738A1 (en) 2003-11-07 2005-08-11 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
EP2616442B8 (en) 2010-09-14 2018-10-17 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
PH12013501837A1 (en) * 2011-03-11 2013-11-18 Celgene Corp Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
KR101446680B1 (ko) 2013-02-08 2014-10-07 한국과학기술연구원 ｍＧｌｕＲ1 길항제로 작용하는 사이에노피리미디논 유도체
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
JP2018535958A (ja) 2015-10-27 2018-12-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としての置換インダゾール化合物及びその使用
KR20180095094A (ko) * 2016-01-08 2018-08-24 셀진 코포레이션 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
US10040804B2 (en) * 2016-12-21 2018-08-07 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
US10406165B2 (en) * 2017-03-14 2019-09-10 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516821A (ja) * 2013-04-17 2016-06-09 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
WO2017161119A1 (en) * 2016-03-16 2017-09-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NATURE, vol. 535, JPN6023008352, 2016, pages 252 - 257, ISSN: 0005003423 *

Also Published As

Publication number Publication date
AU2019243186A1 (en) 2020-10-15
CN112313236A (zh) 2021-02-02
US20190322682A1 (en) 2019-10-24
TW202003524A (zh) 2020-01-16
CA3094988A1 (en) 2019-10-03
US10584133B2 (en) 2020-03-10
WO2019191451A1 (en) 2019-10-03
EP3774815A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
JP2021519786A (ja) チエノピリミジノン化合物
US11345714B2 (en) Compounds targeting proteins, compositions, methods, and uses thereof
US11400084B2 (en) Aminoamide compounds
US10562917B2 (en) Chimeric compounds targeting proteins, compositions, methods, and uses thereof
US11285218B2 (en) Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
JP6629885B2 (ja) タンパク質を標的とする化合物、その組成物、方法、および使用
JP2022510313A (ja) Ｈｅｌｉｏｓの低分子分解誘導剤および使用方法
CN113498342A (zh) 参与协同结合的化合物和其用途
JP2021527098A (ja) 縮合チオフェン化合物
JP2022507267A (ja) 置換イソインドリノン
TW202019936A (zh) 雙功能化合物
CN105073750A (zh) 布鲁顿氏酪氨酸激酶抑制剂
US10723705B2 (en) Heterocyclic compounds and uses thereof
JP2022522890A (ja) 芳香族誘導体、その調製方法および医薬用途
US10550125B2 (en) Prodrugs of imidazotriazine compounds as CK2 inhibitors
US20250092043A1 (en) Kinase Inhibitors and Degraders
HK40005135A (en) Pyrazole derivatives, compositions and therapeutic use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220325

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231002